Adicet Bio (ACET) CFO Harvey Brian Nicholas Receives Award

What Happened
Harvey Brian Nicholas, Chief Financial Officer of Adicet Bio (ACET), received an award/derivative grant of 43,361 shares on 2026-03-25. The Form 4 lists the acquisition price as $0.00 (no upfront cash paid). This is an award/compensation grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-25; Form 4 filed 2026-03-27 (appears timely).
• Grant: 43,361 derivative shares reported at $0.00 per share (total cash paid $0).
• Vesting: Footnote F1 — 1/48th of the shares vest on each of the next 48 monthly anniversaries of the grant date, contingent on continued service.
• Shares owned after transaction: not specified in the supplied filing details.
• No 10b5-1 plan, cashless exercise, or tax-withholding sale is reported in this filing.

Context
This is a standard time‑based compensation award (likely RSUs or a similar derivative instrument) intended to retain the CFO over the next four years; it does not represent an immediate market purchase or sale. Retail investors should watch future Form 4s for vesting completions or any subsequent sales that will show economic impact.